New Delhi, 27 Mar, 2015: German generic drugmaker Stada struck an alliance with family-owned Hetero Drugs Ltd of India to gain access to active ingredients for cancer drugs, Stada said on Thursday.
As part of the agreement in principle, with details yet to be hammered out, Stada will get exclusive marketing rights in Europe for generic oncology drugs developed and produced by Hetero. Stada will also get a sub-licence in further regions outside India and the United States.
The alliance covers cancer drugs that will lose patent protection between 2016 and 2020 and Stada will decide at a later stage whether Hetero compounds will also go its existing oncology drugs, Stada Chief Executive Hartmut Retzlaff said at a press conference. Reuters
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…